Abbott Laboratories (ABT) : Edmond De Rothschild (italia) Sgr Spa reduced its stake in Abbott Laboratories by 5.74% during the most recent quarter end. The investment management company now holds a total of 182,724 shares of Abbott Laboratories which is valued at $6.9 Million after selling 11,131 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on May 12, 2016.Abbott Laboratories makes up approximately 10.05% of Edmond De Rothschild (italia) Sgr Spa’s portfolio.
Other Hedge Funds, Including , Mosaic Family Wealth reduced its stake in ABT by selling 799 shares or 14.6% in the most recent quarter. The Hedge Fund company now holds 4,672 shares of ABT which is valued at $175,667. Abbott Laboratories makes up approx 0.08% of Mosaic Family Wealth’s portfolio.Focused Wealth Management Inc reduced its stake in ABT by selling 95 shares or 4.61% in the most recent quarter. The Hedge Fund company now holds 1,964 shares of ABT which is valued at $73,846. Abbott Laboratories makes up approx 0.04% of Focused Wealth Management Inc’s portfolio.Isthmus Partners boosted its stake in ABT in the latest quarter, The investment management firm added 4,629 additional shares and now holds a total of 140,519 shares of Abbott Laboratories which is valued at $5.3 Million. Abbott Laboratories makes up approx 1.76% of Isthmus Partners’s portfolio.Bruderman Asset Management boosted its stake in ABT in the latest quarter, The investment management firm added 12 additional shares and now holds a total of 4,023 shares of Abbott Laboratories which is valued at $151,265. Abbott Laboratories makes up approx 0.05% of Bruderman Asset Management’s portfolio.Aspen Investment Management Inc reduced its stake in ABT by selling 450 shares or 8.27% in the most recent quarter. The Hedge Fund company now holds 4,990 shares of ABT which is valued at $194,111. Abbott Laboratories makes up approx 0.18% of Aspen Investment Management Inc’s portfolio.
Abbott Laboratories opened for trading at $37.55 and hit $37.78 on the upside on Friday, eventually ending the session at $37.6, with a gain of 0.97% or 0.36 points. The heightened volatility saw the trading volume jump to 78,07,640 shares. Company has a market cap of $55,240 M.
On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.